|

New once-daily CaloMist™ is the
sting-free alternative to painful intramuscular B12 therapy.
• Maintains consistent serum B12 levels.(1*)
• Effectiveness
of intramuscular therapy — without the pain of injection (1*)
• Convenient, once-daily dosing
• Easy-to-use nasal spray
• Easy-to-remember
dosing schedule — fits into your daily routine
• Safe,
well tolerated, and preferred by patients (1*, 2)
Why does CaloMist™ represent a new era in B12 therapy?
It’s
the only daily nasal spray that provides the effectiveness of intramuscular
therapy
without the inconvenience and pain.
Click here to
view the complete Prescribing Information.
How can you get new CaloMist™?
CaloMist™ is available with a doctor’s
prescription through your local pharmacist.
For
more information,
please visit www.calomist.com or call 1.800.343.0164.
Important Safety Information:
CaloMist™ (cyanocobalamin, USP)
is indicated for the maintenance of vitamin B12 concentrations after
normalization with intramuscular vitamin B12 therapy in patients with
B12 deficiency who have no nervous system involvement. CaloMist™ is
contraindicated in patients with sensitivity to cobalt, vitamin B12, or
any component of the medication. Vitamin B12 concentrations must be
monitored. Patients with declining or abnormally low vitamin B12
concentrations should be switched back to intramuscular vitamin B12
injections. Effectiveness in patients with nasal pathology or with
other concomitant nasal drugs has not been determined. Cyanocobalamin
causes optic nerve atrophy in patients with Leber’s disease; do not use
this product in these patients. Anaphylaxis and angioedema have been
reported with parenteral vitamin B12 products. The most common side
effects of CaloMist™ are arthralgia, bronchitis, dizziness, headache,
nasal discomfort, nasopharyngitis, rash, and rhinorrhea.
Manufactured by Fleming Pharmaceuticals, St. Louis County, MO. CaloMist is a trademark of Fleming Pharmaceuticals.
REFERENCES PAGE
©2008 Fleming Pharmaceuticals All rights reserved CM7119 January 2008 W079 Rev 1207
|